GNG13: A Potential Drug Target for Various Diseases (G51764)

Target Name: GNG13

NCBI ID: G51764

GNG13

GNG13: A Potential Drug Target for Various Diseases

GNG13 (HG3J) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including neurodegenerative disorders, pain, and inflammation. GNG13 is a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression and has been associated with the development and progression of various diseases.

One of the key features of GNG13 is its ability to interact with other proteins, particularly with the protein heat shock protein (HSP70). GNG13 has been shown to physically interact with HSP70 and can cause HSP70 to alter its stability and localization in the cell. This interaction between GNG13 and HSP70 has important implications for the regulation of cellular processes, including protein folding, localization, and degradation.

In addition to its interaction with HSP70, GNG13 has also been shown to play a role in the regulation of gene expression. GNG13 has been shown to act as a negative regulator of the gene encoding the protein BCL2 (B cell lymphoma 2), which is associated with the development of various diseases, including cancer. This interaction between GNG13 and BCL2 has implications for the regulation of cellular processes that are critical for the development and progression of these diseases.

GNG13 has also been shown to play a role in the regulation of pain perception. GNG13 has been shown to regulate the expression of genes involved in pain perception, including the neurotransmitter GABA (纬-amino-尾-keto acid). This interaction between GNG13 and GABA has important implications for the regulation of pain perception and the development of pain-related disorders.

GNG13 has also been shown to play a role in the regulation of inflammation. GNG13 has been shown to regulate the expression of genes involved in inflammation, including the cytokine interferon-纬 (IFN-纬). This interaction between GNG13 and IFN-纬 has important implications for the regulation of inflammatory responses and the development of inflammatory disorders.

GNG13 has also been shown to play a role in the regulation of cellular aging. GNG13 has been shown to act as a negative regulator of the gene encoding the protein p53 (stress protein), which is involved in the regulation of cellular aging and the development of age-related diseases. This interaction between GNG13 and p53 has important implications for the regulation of cellular aging and the development of age-related diseases.

In conclusion, GNG13 is a gene that has been shown to play a role in the regulation of various cellular processes and has been associated with the development and progression of various diseases. GNG13's ability to interact with other proteins, particularly with HSP70, has important implications for the regulation of protein folding, localization, and degradation. In addition, GNG13's ability to act as a negative regulator of the gene encoding BCL2 and to regulate the expression of genes involved in pain perception, inflammation, and cellular aging suggests that it may be a potential drug target or biomarker for the treatment of these diseases. Further research is needed to fully understand the role of GNG13 in the regulation of cellular processes and its potential as a drug target or biomarker.

Protein Name: G Protein Subunit Gamma 13

Functions: Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction

The "GNG13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GNG13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets